Get the Stockscreener App
1.6801
13.42%
0.1901
Ocugen Inc stock is traded at $1.6801, with a volume of 3.53M.
It is up +13.42% in the last 24 hours and up +14.19% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.49
Open:
$1.535
24h Volume:
3.53M
Relative Volume:
0.84
Market Cap:
$524.70M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-6.2226
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
+4.32%
1M Performance:
+14.19%
6M Performance:
+64.08%
1Y Performance:
+123.46%
1-Day Range:
$1.53
$1.69
1-Week Range:
$1.47
$1.84
52-Week Range:
$0.515
$1.96
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.68 | 465.36M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.24 | 117.00B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
756.53 | 78.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
821.22 | 50.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
375.82 | 48.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.56 | 37.81B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen prices $22.5 million common stock offering at $1.50 per share - Investing.com Nigeria
Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease - MSN
Ocugen Announces $22.5 Million Public Stock Offering - TipRanks
Ocugen Signs Underwriting Agreement With Oppenheimer & Co - TradingView — Track All Markets
Form 424B5 Ocugen, Inc. - StreetInsider
Ocugen shares slide after company prices $22.5 million equity raise - MSN
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock - Ocugen, Inc.
Ocugen (OCGN) Prices $22.5 Million Stock Offering - GuruFocus
Ocugen drops on stock offering - TradingView — Track All Markets
Ocugen (OCGN) Prices Stock Offering to Raise $22.5 Million - GuruFocus
Ocugen prices $22.5M common stock offering at $1.50 per share - MSN
Ocugen stock falls after pricing $22.5 million common share offering By Investing.com - Investing.com Nigeria
Ocugen stock falls after pricing $22.5 million common share offering - Investing.com
Ocugen Announces Pricing Of $22.5 Million Offering Of Common Stock - TradingView — Track All Markets
Ocugen Strikes $187.5 Million Licensing Deal With Kwangdong for Gene Therapy in Korea - MSN
Ocugen (OCGN) Is Down 12.6% After Positive Phase 2 OCU410 Data in Geographic Atrophy - simplywall.st
Gene Therapy Slows Vision Loss in Stargardt Trial, Fueling Hope for First Treatment - mychesco.com
Ocugen's (OCGN) "Buy" Rating Reiterated at Chardan Capital - MarketBeat
OCGN Analyst Rating Maintains "Buy" with $7.00 Price Target | OC - GuruFocus
Aug Rallies: Is Ocugen Inc undervalued by DCF analysisEarnings Growth Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
Ocugen, Inc. (NASDAQ:OCGN) Short Interest Update - MarketBeat
Short Squeeze: Will Ocugen Inc benefit from sector rotation2025 Technical Patterns & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Forecast Cut: Will Ocugen Inc benefit from sector rotationPortfolio Performance Summary & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Ocugen Shares Stabilize Following Critical Clinical Data Release - AD HOC NEWS
Ocugen Shares Face Scrutiny Over Clinical Data Anomaly - AD HOC NEWS
Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data (NASDAQ:OCGN) - Seeking Alpha
Ocugen reports positive data for gene therapy in geographic atrophy By Investing.com - Investing.com Nigeria
Ocugen Shares Retreat as Clinical Data Fails to Meet Elevated Expectations - AD HOC NEWS
Ocugen’s ArMaDa Trial Sails With Positive Data For OCU410 - Citeline News & Insights
Ocugen (OCGN) Reports 46% Lesion Reduction in OCU410 Mid-Stage Trial - Intellectia AI
Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage - Benzinga
OS Therapies Bone Cancer Trial Data Strengthens FDA Case - Benzinga
Ocugen Faces Mounting Challenges in Vaccine Market - StocksToTrade
Ocugen Faces Sharp Stock Drop Amid Business Challenges - timothysykes.com
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen, Inc.
Ocugen posts mid-stage trial data for GA therapy - MSN
Ocugen Reports Encouraging 12-Month Data for OCU410 - TipRanks
Ocugen (OCGN) Reports Promising Mid-Stage Trial Results for OCU4 - GuruFocus
Ocugen posts mid-stage trial data for GA therapy (OCGN:NASDAQ) - Seeking Alpha
Ocugen reports positive data for gene therapy in geographic atrophy - Investing.com
Ocugen rises as gene therapy shows promise for blinding eye disease - TradingView — Track All Markets
Ocugen announces positive preliminary phase 2 data from Ocu410 modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration - marketscreener.com
Ocugen Announces Positive Preliminary Phase 2 Data From Ocu410 Modifier Gene Therapy For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration - TradingView — Track All Markets
Eye gene therapy for geographic atrophy slows lesions 46% in study - Stock Titan
Ocugen Inc. Stock Rises Wednesday, Outperforms Market - 富途资讯
Ocugen Shares Surge Ahead of Key Clinical Data Announcement - AD HOC NEWS
Ocugen (NASDAQ:OCGN) Hits New 1-Year HighHere's Why - MarketBeat
Ocugen Shares Surge Ahead of Pivotal Clinical Data Release - AD HOC NEWS
Ocugen to host webcast on OCU410 Phase 2 clinical trial results - Investing.com Nigeria
Ocugen (NASDAQ:OCGN) Trading Down 5.9%Should You Sell? - MarketBeat
Why The Narrative Around Ocugen (OCGN) Is Shifting After New Fair Value Updates - Yahoo Finance
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.15%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):